Qiagen to develop companion Dx for Pfizer lung cancer drug
This article was originally published in Clinica
Executive Summary
Expanding on their existing partnership, Qiagen has agreed to develop a companion diagnostic for Pfizer, for use with dacomitinib, the latter's late-clinical stage non-small cell lung cancer (NSCLC) drug. Financial terms of the deal were not disclosed.